EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins

Journal of Neuro-Oncology

Volumn 95, Issue 2, 2009, Pages 175-184

  Horita, Henrick ^a   Thorburn, Jacqueline ^a   Frankel, Arthur E ^b   Thorburn, Andrew ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Apoptosis; Autophagy; Diphtheria toxin; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DIPHTHERIA TOXIN TARGETED EPIDERMAL GROWTH FACTOR RECEPTOR FUSION PROTEIN; FLICE INHIBITORY PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; LEXATUMUMAB; MAPATUMUMAB; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN DEPLETION; TREATMENT RESPONSE; TUMOR CELL;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CASPASES; DIPHTHERIA TOXIN; DRUG SYNERGISM; ENZYME ACTIVATION; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOBLOTTING; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350018066     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9914-4     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66. doi: 10.3322/ canjclin.57.1.43
2. Polednak AP, Flannery JT (1995) Brain, other central nervous system, and eye cancer. Cancer 75:330-337. doi: 10.1002/1097-0142(19950101)75:1+ <330::AID-CNCR2820751315>3.0.CO;2-5
3. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, Cavenee WK (2002) The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 61:215-225. Discussion 226-219
4. Kanzawa T, Ito H, Kondo Y, Kondo S (2003) Current and future gene therapy for malignant gliomas. J Biomed Biotechnol 2003:25-34. doi: 10.1155/S1110724303209013
5. Thorburn A, Thorburn J, Frankel AE (2004) Induction of apoptosis by tumor cell-targeted toxins. Apoptosis 9:19-25. doi: 10.1023/ B:APPT.0000012118.95548.88
6. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559-565. doi: 10.1038/nrc1891
7. Holmes RK (2000) Biology and molecular epidemiology of diphtheria toxin and the tox gene. J Infect Dis 181(Suppl 1):S156-S167. doi: 10.1086/ 315554
8. Morimoto H, Bonavida B (1992) Diphtheria toxin- and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha. J Immunol 149:2089-2094
9. Kageyama A, Kusano I, Tamura T, Oda T, Muramatsu T (2002) Comparison of the apoptosis-inducing abilities of various protein synthesis inhibitors in U937 cells. Biosci Biotechnol Biochem 66:835-839. doi: 10.1271/ bbb.66.835
10. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME (2007) Molecular targets of glioma invasion. Cell Mol Life Sci 64:458-478. doi: 10.1007/s00018-007-6342-5
11. Liu TF, Cohen KA, Ramage JG, Willingham MC, Thorburn AM, Frankel AE (2003) A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res 63:1834-1837
12. Liu TF, Hall PD, Cohen KA, Willingham MC, Cai J, Thorburn A, Frankel AE (2005) Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res 11:329-334
13. Hall WA, Rustamzadeh E, Asher AL (2003) Convection-enhanced delivery in clinical trials. Neurosurg Focus 14:e2. doi: 10.3171/foc.2003.14.2.3
14. Hall WA, Sherr GT (2006) Convection-enhanced delivery: Targeted toxin treatment of malignant glioma. Neurosurg Focus 20:E10. doi: 10.3171/ foc.2006.20.4.15
15. Ashkenazi A, Herbst RS (2008) To kill a tumor cell: The potential of proapoptotic receptor agonists. J Clin Invest 118:1979-1990. doi: 10.1172/JCI34359
16. Johnstone RW, Frew AJ, Smyth MJ (2008) The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 8:782-798. doi: 10.1038/nrc2465
17. Thorburn A (2007) Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling. J Thorac Oncol 2:461-465. doi: 10.1097/ JTO.0b013e31805fea64
18. Camidge DR (2007) The potential of death receptor 4- and 5-directed therapies in the treatment of lung cancer. Clin Lung Cancer 8:413-419. doi: 10.3816/CLC.2007.n.024
19. Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7:1001-1012. doi: 10.1038/nrd2637
20. Jin Z, El-Deiry WS (2006) Distinct signaling pathways in TRAIL- versus tumor necrosis factor-induced apoptosis. Mol Cell Biol 26:8136-8148. doi: 10.1128/MCB.00257-06
21. Thorburn A, Behbakht K, Ford H (2008) TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them. Drug Resist Updat 11:17-24. doi: 10.1016/j.drup.2008.02.001
22. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195. doi: 10.1038/40657
23. Wilkinson JC, Wilkinson AS, Scott FL, Csomos RA, Salvesen GS, Duckett CS (2004) Neutralization of Smac/Diablo by inhibitors of apoptosis (IAPs). A caspase-independent mechanism for apoptotic inhibition. J Biol Chem 279:51082-51090. doi: 10.1074/jbc.M408655200
24. Dancey JE, Chen HX (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 5:649-659. doi: 10.1038/nrd2089
25. Thorburn J, Horita H, Redzic J, Hansen K, Frankel AE, Thorburn A (2009) Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ 16:175-183. doi: 10.1038/cdd.2008.143
26. Liu TF, Willingham MC, Tatter SB, Cohen KA, Lowe AC, Thorburn A, Frankel AE (2003) Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells. Bioconjug Chem 14:1107-1114. doi: 10.1021/bc034111+
27. Komatsu N, Oda T, Muramatsu T (1998) Involvement of both caspase-like proteases and serine proteases in apoptotic cell death induced by ricin, modeccin, diphtheria toxin, and Pseudomonas toxin. J Biochem 124:1038-1044
28. Horita H, Frankel AE, Thorburn A (2008) Acute myeloid leukemia-targeted toxins kill tumor cells by cell type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death. Leukemia 22:652-655. doi: 10.1038/sj.leu.2404956
29. Thorburn J, Frankel AE, Thorburn A (2003) Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein. Clin Cancer Res 9:861-865
30. Thorburn J, Frankel AE, Thorburn A (2009) Regulation of HMGB1 release by autophagy. Autophagy 5:93-95
31. Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621-681. doi: 10.1124/pr.58.3.10
32. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55. doi: 10.1016/0065-2571(84)90007-4
33. Kawakami M, Kawakami K, Puri RK (2002) Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol Cancer Ther 1:999-1007
34. Kawakami M, Kawakami K, Puri RK (2003) Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways. Int J Cancer 103:45-52. doi: 10.1002/ijc.10778
35. Ravikumar B, Berger Z, Vacher C, O'Kane CJ, Rubinsztein DC (2006) Rapamycin pre-treatment protects against apoptosis. Hum Mol Genet 15:1209-1216. doi: 10.1093/hmg/ddl036
36. Han J, Hou W, Goldstein LA, Lu C, Stolz DB, Yin XM, Rabinowich H (2008) Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells. J Biol Chem 283:19665-19677. doi: 10.1074/jbc.M710169200
37. Stish BJ, Oh S, Vallera DA (2008) Anti-glioblastoma effect of a recombinant bispecific cytotoxin cotargeting human IL-13 and EGF receptors in a mouse xenograft model. J Neurooncol 87:51-61. doi: 10.1007/s11060-007-9499-8
38. Sampson JH, Akabani G, Archer GE, Berger MS, Coleman RE, Friedman AH, Friedman HS, Greer K, Herndon JEII, Kunwar S, McLendon RE, Paolino A, Petry NA, Provenzale JM, Reardon DA, Wong TZ, Zalutsky MR, Pastan I, Bigner DD (2008) Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol 10:320-329. doi: 10.1215/ 15228517-2008-012
39. Pollack IF, Erff M, Ashkenazi A (2001) Direct stimulation of apoptotic signaling by soluble Apo2 l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 7:1362-1369
40. Saito R, Bringas JR, Panner A, Tamas M, Pieper RO, Berger MS, Bankiewicz KS (2004) Convection-enhanced delivery of tumor necrosis factor-related apoptosis-inducing ligand with systemic administration of temozolomide prolongs survival in an intracranial glioblastoma xenograft model. Cancer Res 64:6858-6862. doi: 10.1158/0008-5472.CAN-04-1683